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ABSTRACT: The U.K.’s National Institute for Health and Clinical Excellence (NICE) was 
established to perform three core functions: 1) reduce unwarranted variation in practice 
across the United Kingdom through the development and dissemination of best practice 
evidence-based standards; 2) encourage fast diffusion and uniform uptake of high-value 
medical innovations; and 3) ensure the taxpayers’ money is invested in the National Health 
Service so that health benefit is maximized. NICE decisions are made by independent 
committees of health professionals, academics, and industry and lay representatives. More 
than 2,000 experts engage with NICE processes throughout the year. NICE committees 
consider comparative clinical and cost effectiveness, social values (including impact on 
equity), and U.K. and European Union legislation when making their decisions.
                    
OvERvIEW
The establishment of the National Institute for Health and Clinical Excellence 
(NICE) has been followed by a time of rapid increases in funding for the United 
Kingdom’s National Health Service (NHS). The Institute’s objectives are to 
assure that the new investment yields maximum health benefit, reduces unwar-
ranted variation in medical practice, and encourages rapid diffusion of high-
value new technologies. NICE is structured as an independent authority, with an 
appointed board and an annual budget of about $70 million.
NICE develops four types of products: clinical guidelines for whole 
treatment pathways; technology assessments for (mostly) new drugs, devices, 
and diagnostic tests; guidance on safety and efficacy of surgical and invasive 
diagnostic procedures; and public health guidance for health promotion and 
disease prevention.
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NICE decisions are made by independent 
committees of health professionals, academics, and 
industry and lay representatives who offer their time 
usually for free. More than 2,000 experts engage with 
NICE processes throughout the year. NICE committees 
consider comparative clinical and cost effectiveness, 
social values (including impact on equity), and U.K. 
and European Union  legislation when making their 
decisions. While NICE decisions could be overridden 
by the Secretary of State for Health, this has not 
happened yet.
While its program of work, especially for new 
technologies, is reviewed by the Health Ministry, NICE 
is responsible for the process of topic selection. All 
new cancer drugs and most but not all new drugs for 
other indications are considered by NICE. Criteria for 
selecting a new technology for review include potential 
for significant costs (or savings) or health benefits, and 
unexplained variation in current practice.
The methods and process for making deci-
sions, as well as the actual material used to inform 
a specific recommendation, are placed in the public 
domain. Confidential commercial and academic data 
are accepted but kept to a minimum. Committee meet-
ings (apart from their final stage) and appeals are held 
in public. Stakeholders engage with NICE throughout 
the process of selecting a topic, developing and dis-
seminating the final product as well as the process for 
reviewing NICE’s methodology. Industry and profes-
sional associations as well as patients are key NICE 
stakeholders involved in all the above stages through 
consultation, submission of evidence and oral testimo-
nies, membership of decision-making committees, and 
the right to appeal decisions.
NICE is a user rather than producer of compara-
tive effectiveness research, relying on work commis-
sioned from academic networks or (for the recently 
developed single technology appraisal process) 
evidence presented by the sponsor of a new drug or 
technology. NICE is flexible in considering evidence, 
focusing on the quality rather than the specific type 
of available studies. It is experimenting with schemes 
such as risk-sharing or conditional reimbursement to 
allow use of new technologies while evidence is being 
developed. NICE recommendations on technologies 
are subject to appeal; about one-third of appraisals are 
appealed, and half these appeals result in some change 
in the guidance.
Guidance is disseminated electronically to cli-
nicians, hospital managers, local purchasers (primary 
care trusts), and industry, professional, and patient 
organizations. For example, in the case of clinical 
guidelines, the respective Royal College holds a launch 
event to which all its specialist members are invited. 
NICE operates customized e-mail alert services, runs 
an annual conference, and sponsors a network of 
‘implementation consultants’ to interact with frontline 
managers and clinicians.
The government has taken several steps to 
improve compliance with NICE guidance and reduce 
local variation. Local purchasers of care (primary care 
trusts) are required to fund newly recommended tech-
nologies and hospitals to make them available when 
requested by a patient and his or her physician; com-
pliance is increasingly considered as part of provider 
accreditation, and a new NHS Constitution makes 
access to NICE-recommended treatments a right for 
everyone in England. While it is difficult to separate 
the effects of NICE guidance from other factors affect-
ing utilization trends, there is evidence that the system 
has responded rapidly to both positive and negative 
specific recommendations, while hospital compliance 
with NICE guidance has risen steadily.
NICE has generally been supported by the pub-
lic and by politicians, despite some highly publicized 
and controversial decisions. Overall, NICE guidance 
is estimated to have increased NHS expenditures, 
because its focus is on promoting the use of high-value 
services, rather than simply cost containment.
A BRIEF HISTORY OF NICE
In 1997, the newly elected U.K. Labour government 
announced its intention to support decision-makers 
across the NHS through sponsoring the generation and 
dissemination of evidence of comparative effective-
ness. Following years of underinvestment, the NHS 
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in the late 1990s was faced with a number of chal-
lenges. A lack of evidence-based quality standards 
for best practice was partially responsible for unwar-
ranted sociodemographic and geographical variation. 
Adoption of new technologies was slow, possibly 
due to an inherently conservative attitude on behalf 
of health care professionals, coupled with budgetary 
restrictions. And there was no clear procedural and 
methodological framework to guide additional public 
investment toward those interventions and practices 
representing best value for money.
The lack of a consistent, transparent, scientific, 
and contestable process for making investment deci-
sions was possibly one trigger for the establishment 
of NICE. The launch of sildenafil (Viagra) in the U.K. 
market in 1998 was followed by a very public debate 
on whether it should be covered by the NHS. A restric-
tive ministerial decision, mainly due to budgetary con-
cerns, was later challenged in court by the manufac-
turer, Pfizer. The court ruled in favor of Pfizer, based 
on what was seen to be a deficient process leading to 
the decision (as opposed to the content of the decision). 
Professional associations, patient organizations, and 
industry called for more transparency and accountabil-
ity in health care policymaking. NICE was launched a 
few months later, in March 1999.
PRINCIPLES, vALUES, AND OBJECTIvES
NICE was established to perform three core functions,1 
which continue to be its main objectives today:
Reduce unwarranted variation in practice 1. 
across the U.K., through the development and 
dissemination of best practice evidence-based 
standards.
Encourage fast diffusion and uniform uptake of 2. 
high-value medical innovations.
Ensure the taxpayers’ money is invested in the 3. 
NHS so that health benefit is maximized.
The objectives are interrelated and directly 
linked to the record increases in NHS funding, more 
than 50 percent in real terms between 2002 and 2008. 
During this period, NICE’s main aim was to target 
the increased health care expenditures toward those 
interventions that are most effective and cost effec-
tive, including accelerating the uptake of good value 
innovation and reducing the discrepancies in access 
and, further downstream, outcomes, across the U.K. 
population. However, with reducing levels of public 
investment in health, NICE is now becoming increas-
ingly focused on targeting waste and optimizing the 
use of new expensive technologies to ensure best value 
for money.
Since its establishment, NICE has applied a set 
of core principles to the way it operates:
Transparency:•	  All stages of the process for 
developing NICE guidance and the methodol-
ogy underpinning guidance development, as 
well as the evidence underpinning the guid-
ance, are put in the public domain, with the 
exception of academic and confidential com-
mercial data. On the latter, NICE insists that 
such confidential information is kept to a mini-
mum and is made publicly available as soon as 
possible after the publication of its guidance. 
In an effort to improve transparency, all NICE 
advisory body meetings are held in public, 
starting autumn 2008.
Scientific	rigor:•	  NICE guidance development 
methods are evidence-based, are constantly 
reviewed and peer-reviewed, and incorporate the 
latest developments in methods research. In fact, 
NICE has boosted investment in publicly funded 
methodology research.
Inclusiveness:•	  NICE identifies all relevant 
stakeholders, including professional and patient 
organizations, the broader academic community, 
budget holders and health care administrators, 
and medical technology manufacturers, and 
provides them with the opportunity to become 
involved in the development of NICE’s specific 
products and overall methods and processes 
through: a) public consultation, broadly open 
to the public, b) submission of written and 
oral evidence, generally more restricted to 
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registered stakeholders, and c) participation in 
the Institute’s decision-making bodies, through a 
dedicated selection process.
Consistency:•	  The processes and methods for 
NICE guidance development are applied across 
all technologies and interventions NICE consid-
ers, with some differences across the different 
programs of work (e.g., appraisals of individual 
technologies vs. clinical guidelines for whole 
care pathways).
Independence:•	  NICE guidance is developed by 
independent advisory bodies whose members 
are drawn from clinicians, professional groups, 
researchers, and patient and public representa-
tives. The Institute operates “at arm’s length” 
from government, which is one of the many 
stakeholders in the overall process, and it issues 
its guidance directly to the NHS.
Review	and	update:•	  All NICE guidance is 
updated at regular intervals—three to four years, 
or earlier if new evidence becomes available.
Timeliness:•	  Timeliness is becoming an 
increasingly important priority for NICE and has 
resulted in an in-depth review of the methods 
and processes and the establishment of the Single 
Technology Appraisal process, discussed below.
NICE’s mission was expanded in 2005 to 
include health promotion and disease prevention, as 
well as a more explicit responsibility to reduce health 
inequalities. In addition to the NHS, NICE guidance is 
now issued directly to local authorities, education and 
transport boards, employers, and other parties with a 
stake in preventative public health interventions.
STRUCTURE AND SIZE, POSITIONING, 
OUTPUTS, AND BUDGETARY IMPACT
NICE was set up as a Special Health Authority, with 
a Board of 12 nonexecutive Directors and a Partners’ 
Council consisting of major stakeholders appointed 
directly by the Secretary of State for Health. (The latter 
meets annually to review NICE’s annual report.) NICE 
employs approximately 330 staff and has an annual 
budget of around $70 million, set to rise to over $180 
million in the next three to four years. At any given 
time, NICE collaborates with approximately 2,000 
experts from around the country in developing indi-
vidual guidance products. NICE is funded directly by 
the Department of Health; however, it issues its recom-
mendations to the NHS and, even though the Secretary 
of State for Health can overturn a NICE decision, this 
has never happened so far. Government can become 
involved in the guidance development process as any 
other NICE stakeholder.
NICE develops four broad types of products:
Clinical guidelines, looking at disease manage-•	
ment strategies, from diagnosis and treatment to 
longer follow-up. Since its establishment, NICE 
has issued over 70 clinical guidelines covering 
primary prevention, diagnosis, and management 
of major diseases such as diabetes, schizophre-
nia, and hypertension. Another 40 are under 
development.
Technology appraisals, assessing the compara-•	
tive clinical and cost effectiveness of specific 
technologies, including drugs, devices, and 
diagnostic tests. NICE has developed guidance 
on the optimal use of around 400 technologies 
(mostly drugs and devices, broken down by 
population subgroup and licensing indication).
Interventional procedures guidance, which •	
assesses the safety and efficacy of surgical and 
interventional diagnostic procedures. Over 250 
have been assessed, mostly surgical procedures 
and diagnostic interventions such as endoscopy 
and ultrasound tests. These assessments are 
the only NICE products that consider clini-
cal effectiveness but not cost; they are thus the 
equivalent, for surgical procedures, of the drug 
licensure process.
Public health guidance, looking at disease •	
prevention and health promotion interventions 
and broader public health programs; 15 public 
health interventions and programs have been 
developed since 2005.
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Table 1 provides some examples of different 
types of NICE guidance.
USING COMPARATIvE EFFECTIvENESS 
RESEARCH TO INFORM POLICY DECISIONS
In an attempt to reduce unexplained geographic varia-
tion in the uptake of new technologies, NICE recom-
mendations for the use of technologies became manda-
tory in July 2003.2 Local purchasers of care (Primary 
Care Trusts, or PCTs) are given a three-month period 
to identify the funding to support the implementation 
of NICE guidance on specific technologies, upon a 
physician’s and patient’s request of the recommended 
treatment. As NICE holds no budget to fund its adop-
tion recommendations, PCTs have to identify and make 
available appropriate funding, a requirement that many 
argue distorts local priorities and results in crowding 
out of non-drug, service delivery-type interventions, 
for which there is usually no mandate. To help address 
this issue, NICE provides PCTs with planning tools to 
prepare them for forthcoming guidance and is increas-
ingly focusing on identifying disinvestment guidance 
to release resources from wasteful practices.
A national review published for the 60th anni-
versary of the NHS in June 2008 introduced an NHS 
Constitution which was ratified by the country’s 
parliament in January 2009. For the first time in NHS 
history, the NHS Constitution describes the basic stan-
dards of care to be expected from the NHS by its users. 
NICE guidance has a central place in this document, 
and NICE recommendations for best practice and 
optimal use of health technologies are designated as 
patients’ rights to care in the NHS.3
In order to ensure NICE guidance and other 
(usually centrally set) quality standards are imple-
mented across the NHS, the government established, 
at the same time as NICE, a monitoring body known 
as the Health Care Commission (HCC). The HCC 
reviewed the performance of NHS providers against a 
number of core and developmental standards. The core 
standards are mandatory and include NICE guidance 
on the safety and efficacy of new interventional proce-
dures4 and on NICE recommendation on specific health 
technologies, as described above. HCC was superceded 
in April 2009 by the Care Quality Commission (CQC), 
which will introduce a new system of accreditation 
and performance management standards for provid-
ers drawing on, among other quality metrics, specific 
NICE recommendations for best practice.
Overall, NICE relies on frontline NHS staff and 
patients for implementing its guidance rather than on 
rigid rules and regulations that force clinicians and 
Table 1. Examples of Guidance Offered by NICE
Guidance Type Year
Intraoperative red blood cell salvage during radical 
prostatectomy or radical cystectomy Interventional procedure 2008
Radiofrequency ablation of hepatocellular carcinoma Interventional procedure 2003
Guidance on the promotion and creation of physical 
environments that support increased levels of physical activity Public health intervention 2008
Interventions to reduce substance misuse among vulnerable 
young people Public health intervention 2007
Management of chronic heart failure in adults in primary and 
secondary care Clinical guideline 2003 (under review)
Prenatal care: routine care for the healthy pregnant woman Clinical guideline 2008
Adalimumab, etanercept and infliximab for ankylosing 
spondylitis (chronic inflammatory arthritis) Technology appraisal 2008
Bortezomib for multiple myeloma Technology appraisal 2007
The clinical effectiveness and cost effectiveness of endometrial 
ablation (fluid-filled thermal balloon and microwave) for 
menorrhagia
Technology appraisal 2004
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commissioners to adopt its recommendations, and 
strives to gain stakeholder buy-in through the inclusive 
nature of the guidance development processes.
PROCESSES AND METHODS
Topic Selection
NICE plays an increasingly central role in selecting the 
topics for developing guidance. Since 2006 NICE has 
been given responsibility for identifying and sifting 
high-priority topics, according to predetermined cri-
teria, including: broad policy priorities; potential bud-
getary impact; potential to improve health outcomes; 
current variation in practice; availability of relevant 
evidence; and potential of NICE guidance to add value. 
However, final responsibility for the referral of mostly 
new technologies still remains with the Secretary of 
State for Health.5 A number of sources are used to 
derive topics, including a dedicated horizon-scanning 
service funded by the Department of Health and sug-
gestions by individual members of the public through 
an open Web-based process.
NICE puts the recommended topics before 
disease-specific consideration panels led by National 
Clinical Directors in the respective areas (e.g., cardio-
vascular disease, public health, mental health, cancer). 
These panels draw their membership from profes-
sional associations, industry, academia, and the general 
public.
Transparency and inclusiveness are important 
characteristics of the NICE topic selection process; 
however, there remains a clear tension between being 
timely and inclusive (including getting public and 
expert feedback through lengthy consultation rounds), 
a tension that applies across the whole of the NICE 
guidance development process.
Methods
Considerations. NICE committees consider compara-
tive clinical and cost effectiveness, social values, 
including impact on equity, and U.K. and European 
Union legislation when making its decisions. Costs are 
considered through an incremental cost-effectiveness 
analysis and a judgement is made on value for money 
based on a threshold range of £20,000–£30,000 per 
QALY (quality-adjusted life year—one QALY is the 
equivalent of a year in full health). This range allows 
consistency of decision-making across disease areas 
and over time and is broadly consistent with empirical 
evidence of cost per QALY of other decisions made 
by local NHS purchasers and by willingness to pay 
surveys. Technologies of significantly higher cost per 
QALY have been approved by NICE based on other 
considerations.
Primary research and evidence synthesis. NICE 
is often described as a comparative effectiveness 
research (CER) entity. However, NICE is a user rather 
than a producer of CER. To develop its guidance, 
NICE depends on a publicly funded network of aca-
demic institutions working together under the auspices 
of the National Institute for Health Research (NIHR). 
On behalf of NICE, the Department of Health com-
missions designated NIHR academic groups to under-
take: a) horizon scanning to inform the topic selection 
process, b) evidence syntheses to inform the develop-
ment of guidance on the use of specific technologies, 
and c) starting in 2007, prospective real-world trials 
to address specific uncertainties identified during the 
guidance development process.6 Similarly, the Medical 
Research Council receives public funding to support 
research on methodologies, including modeling tools 
for making conditional coverage decisions and ways 
for incorporating equity considerations into the deci-
sion-making algorithm.
NICE’s overall approach to evidence does not 
follow the conventional evidential hierarchies, but it is 
driven mainly by the type of policy and clinical prac-
tice question that needs to be answered and focuses on 
the quality (rather than the type) of the study used to 
address this question.7 Such evidence includes good 
quality meta-analyses and systematic reviews of ran-
domized controlled trials (RCTs), head-to-head RCT 
comparisons of the technologies under consideration, 
and also different types of nonexperimental studies, 
such as prospective cohort, registries, and epide-
miological analyses. Unpublished evidence deemed 
to be either academic or confidential commercial 
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information can also be considered; however, NICE 
encourages stakeholders to keep such submissions to a 
minimum.
Furthermore, NICE relies on decision analyses 
rather than primary research, which allows consider-
ation of multiple sources of evidence; extrapolation 
beyond usually short time horizons of RCTs; incorpo-
ration of the epidemiological data specific to the U.K. 
population; consideration of alternative comparators 
and costs; and quantification of uncertainty and of 
the implications of making the wrong decision, issues 
hardly addressable through a single explanatory RCT. 
Finally, NICE also considers patient surveys and 
patient and professional expert opinion.
NICE is also experimenting with risk-sharing 
schemes or conditional reimbursement decisions. 
These options, which link policy and practice recom-
mendations to evidence generation, are particularly 
relevant in circumstances of increased uncertainty—
as is the case with new drugs at the time of receiving 
marketing authorization, or with diagnostic tests and 
surgical procedures, which are usually accompanied by 
limited evidence of impact on health outcomes. Risk-
sharing/patient access schemes now form part of the 
new national policy on drug pricing, to allow the gen-
eration of real-life information on the clinical perfor-
mance and cost of new drugs where the evidence base 
is too weak to inform coverage and reimbursement 
decisions. Both NICE and the British Pharmaceutical 
Industry Association are fully supportive of and work-
ing together on this initiative.
Appeal
NICE recommendations for the use of technologies 
can be appealed by stakeholders, such as patient and 
professional organizations, commissioners, and medi-
cal product manufacturers on the following grounds: a) 
perversity, in that no reasonable group of people would 
have formulated recommendations as presented by 
NICE; b) violation of NICE’s procedural rules; and c) 
a decision by NICE exceeding its scope of responsibili-
ties. Appeals are heard by a panel consisting of non-
executive NICE directors, patient advocates, industry, 
and NHS representatives. Approximately one of 
three appraisals are appealed and almost half of these 
appeals are upheld. If unsuccessful at the appeal stage, 
stakeholders can seek a judicial review of the guidance. 
This has happened on three occasions since NICE was 
set up 10 years ago.
Conflict-of-Interest Policies
NICE has a detailed policy on declaring and handling 
conflicts of interests for its members of the Board, 
staff, and advisory body members, as well as external 
experts providing their insight to individual guidance 
products. No personal financial interests are accept-
able in the case of members of the NICE Board, NICE 
employees, and employees of organizations directly 
contracted by NICE who are involved in the develop-
ment of NICE products.
THE MEDIA AND PUBLIC PERCEPTIONS
Both NICE and the NHS are the subject of intense 
media attention. Although NICE generally receives 
balanced media coverage,8 certain parts of the U.K. 
press have increasingly adopted a critical approach to 
the Institute’s work.9 Independently-conducted NICE-
sponsored opinion polls indicate that, while awareness 
of NICE among the general population has increased 
between 2002 and 2007, public attitudes have remained 
roughly the same. Over 70 percent of those familiar 
with NICE stated they are neutral or positive about 
NICE, despite a number of controversial decisions 
that received extensive press attention during that time 
(e.g., restrictive guidance for drugs for Alzheimer’s 
disease, leading to an ongoing legal battle).
Politicians’ views of NICE have changed over 
the years. In their 2008 parliamentary enquiry into 
NICE, the multipartisan Health Select Committee 
concluded: “NICE does a vital job in difficult circum-
stances. The development of more and more health 
technologies and procedures, alongside rising patient 
expectations and the aging population, is going to 
make it even more difficult in the future. Health care 
budgets in England, as in other countries, are lim-
ited. Patients cannot expect to receive every possible 
8 The CommonwealTh Fund
treatment. Demand outstrips resources and priorities 
have to be determined. In other words rationing is 
essential, and NICE has a key role to play. Given the 
difficult environment, NICE requires the backing of 
the Government. NICE must not be left to fight a lone 
battle to support cost and clinical effectiveness in the 
NHS.”10
IMPACT ON POLICY AND PRACTICE: 
SELECTED CASE STUDIES AND  
OvERALL TRENDS
When NICE was first established, implementation of 
its guidance was explicitly excluded from its mission. 
However, as unwarranted geographic variation in prac-
tice persisted despite national guidance, implementa-
tion of NICE recommendations became a government 
priority and a number of measures were introduced to 
improve uptake. These included the three-month fund-
ing direction discussed above and the establishment of 
a NICE Implementation Directorate in 2004.
This directorate has developed a number of tools 
and interventions for supporting the uptake of NICE 
guidance at the local level, including audit criteria, 
educational tools, a network of “implementation con-
sultants” operating at the local level, guides to chang-
ing provider behavior, budget impact tools adaptable to 
the local setting, and a “forward planner” to help com-
missioners plan ahead for NICE guidance in the pipe-
line. The implementation directorate is also responsible 
for developing and maintaining a database of uptake 
studies from across the U.K. (www.nice.org.uk/ernie).
More recently, NICE launched an electronic 
portal—NHS Evidence (www.evidence.nhs.uk)—that 
brings together evidence of clinical and cost effective-
ness for patients, professionals, purchasers, and policy-
makers in order to support access to good quality infor-
mation, including NICE guidance, for decision-makers 
across the NHS.
Finally, a number of performance indicators in 
the pay-for-performance scheme for primary care prac-
titioners (Quality and Outcomes Framework—QOF) 
across the U.K. come from NICE best practice guid-
ance, another important means for incentivizing the 
uptake of NICE recommendations.
It is methodologically challenging to assess the 
impact of NICE guidance on practice patterns and, 
even more so, on health outcomes. The lack of a con-
trol group and the multitude of government policies 
and other, often non-health-related, factors affecting 
observed health trends, make attributing causality 
impossible. However, there are numerous case studies 
that show the impact of the use of evidence-based cov-
erage decisions on unwarranted variation in practice 
and on the speed of diffusion of new, good-value-for-
money treatment across the NHS.
According to a report by the National Director 
for Cancer, the uptake of cancer drugs appraised by 
NICE increased by almost 50 percent across the coun-
try from 2003 to 2005, and variation in use dropped 
from three-to-eight fold to two-to-three fold over the 
same period.11 Another national report in 2007 showed 
that NICE advice for the use of multidisciplinary teams 
for managing lung and colon cancer patients was taken 
up by over 95 percent of providers across the NHS. 
There are some examples of very rapid NHS-wide 
response to NICE recommendations on specific tech-
nologies: sharp growth in the use of varenicline for 
smoking cessation after a positive recommendation 
and a steep drop in the use of anakinra for rheumatoid 
arthritis after a negative appraisal. In other cases the 
uptake of guidance is slower and/or less even across 
different parts of the country.
Table 2 gives the results of the annual inspec-
tion (Health Check) of hospitals’ adherence to NICE’s 
recommendations conducted by the Health Care 
Commission (now the Care Quality Commission). 
While these are self-assessment results, there are 
accompanied by spot checks and give an indication  
of providers’ compliance, or at least awareness, of 
NICE guidance.
Overall, NICE adoption decisions have an esti-
mated aggregate cost of over £1.5 billion per year; in 
2006–07, NICE guidance absorbed more than a tenth 
of the growth in health care spending across the NHS. 
Over the same period, the price of DRG-equivalents 
used by the NHS (Health Care Resource Groups—
HRGs) was adjusted upward by almost 1 percent. This 
is expected to increase significantly as new cancer 
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drugs, all of which are now subject to NICE apprais-
als, are included in the HRG price list. It is very hard 
to assess whether spending would have been higher or 
lower had there not been a NICE; however, the gov-
ernment’s explicit objective was for NICE to target 
additional funding toward good value innovation rather 
than to cut costs.
Perhaps the greatest contribution of NICE has 
been to raise awareness among the general public, the 
media, professionals, and industry of the importance of 
making evidence-informed health care resource alloca-
tion decisions in a transparent, inclusive, and method-
ologically robust way.
LESSONS LEARNED: A CRITICAL vIEW
In late 2005 NICE launched the Single Technology 
Appraisal (STA), a new process for assessing medi-
cines closer to the time of marketing authorization. 
This was the result of growing concerns as to the time-
liness of the NICE process. Even though purchasers 
and providers at the local level are expected to make 
their own decisions on the availability of new tech-
nologies while NICE guidance is pending, often there 
are delays in adoption, as local decision-makers prefer 
to wait for definitive NICE guidance. This may be due 
to both the lack of necessary analytical capacity locally 
and budgetary constraints.
In the new process, independent modeling car-
ried out by academic groups commissioned directly by 
the U.K. Department of Health is replaced by a model 
and systematic review of the evidence submitted by 
the technology sponsor. This is then supplemented by 
a critical review undertaken by an external academic 
group. In addition to somewhat reducing the overall 
length of the technology appraisal process, this stream-
lining has two additional implications:
Sponsors are required to undertake a system-•	
atic review to inform the economic evaluation. 
Given limited experience with actual use and the 
(sometimes sensitive) commercial nature of the 
evidence base, sponsor-led systematic reviews 
close to licensing pose practical challenges, 
particularly when they involve accessing con-
fidential data held by a sponsor’s competitors. 
Furthermore, NICE has no means of assessing 
whether all available (published and unpub-
lished) relevant studies are indeed included in 
the sponsor’s submission.12
By definition, STA is about assessing the value •	
of a single (most of the time new) technology 
for a single indication. For follow-on drugs, 
comparing each technology to preexisting 
therapies (rather than to each other) may lead to 
timely positive recommendations for each new 
drug; these may, however, be of limited value to 
NHS purchasers interested in the comparative 
effectiveness of each one against all available 
alternatives across different population groups.
Dependence on sponsor-generated and con-
trolled evidence and limitations as to the comparators 
used make STA an acceptable first screening tool for 
new technologies close to licensing (when most the 
information is held by the sponsors and there are few 
alternative technologies), but a less reliable process 
for informing the NHS as to the best option among 
many new technologies in a class. NICE is attempt-
ing to address these weaknesses by commissioning an 
independent review of the STA process and consider-
ing formal review arrangements for STAs, either in the 
context of clinical guidelines or Multiple Technology 
Appraisals.
Table 2. Hospital Adherence to NICE Recommendations
2005–06 2006–07 2007–08
Compliant 85% 89.3% 95.1%
Insufficient assurance 11% 7.9% *
Not met 4% 2.8% *
* To be confirmed.
10 The CommonwealTh Fund
To improve the quality of industry submissions, 
NICE launched in 2008 a formal program for engaging 
with the medical technologies industry during phase 
II and III trials to help inform trial design, especially 
with regard to outcome measures, types of cost, and 
appropriate comparators. This is a fee-for-service ini-
tiative, aiming at helping technology sponsors better 
understand and respond to decision-makers’ informa-
tional requirements, so that new drugs and devices are 
approved closer to licensing.
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